A Michigan Fall
She loved dry leaves
Essentially the entire issue of the November 27, 2012 NCI
Cancer Bulletin is devoted to a discussion of cancer screening. As both of the groups I try to help are
engaged in just that, I read it with interest (and more than my usual
comprehension.) It is really good stuff,
and (as always) I urge you to read it.
However, I know you won’t, so I will toss out a few observations and
maybe some analysis. I am tempted to
weave a few egregious lies into some future blog, to see if anybody notices and
checks. I promise not to do it this
time, though.
First, there is a long piece by Dr. Virginia Moyer, who is
the head of the USPSTF: that is, the United States Preventative Services Task
Force. This is the group that has caught
so much flack over their recommendation that healthy men not be screened
for prostate cancer using PSA. (All
males over 60 will know very well what that is.) To get current with the Prostate Cancer Wars,
re-read the blog of the same name (3/27/12) and especially the appended
Comments.
It turns out that the USPSTF is an all-volunteer group of 16
and is substantially independent of control by government or anything
else. They were set up in 1984 to
counter the perception that the medical community was neglecting prevention for
cure. They make recommendations for
preventative measures, including screening.
They have had their bad days; one especially bad occurred in 2009, when
they issued guidelines for mammography. They
recommended that women under the age of 50 – and over 75 – be not screened at
all. The AMA went ballistic.
Dr. Moyer does a good job of explaining their
reasoning. Any screening regimen involves
false negatives. False negatives engender
anxiety, discomfort, and expense. In the
case of cancer, there are some which are easily cured – and others that are
incurable. It doesn’t make sense to
screen for these. Pancreatic cancer is a
case in point; there is no viable treatment.
For the rest of cancers, screening might save lives, and whether to screen
or not is a judgment call. I reason that
ovarian cancer is one of these. If
caught early, it’s completely curable; if later, rarely so.
The problem here is that one does not know how to value a
few lives saved relative to a whole bunch of needless treatment and anxiety. I tend to think that one live saved easily
balances a mountain of anxiety, discomfort and expense. But that’s just me.
Another great article concerns the role of statistics. You know Mark Twain’s famous analysis of
statistics. Well, it seems still to be
at work. Some statistics show that the
life-span of cancer victims from diagnosis to death has lengthened dramatically
in recent decades. Good news.
But there is a problem: does this
represent better treatment, or is it simply an artifact of screening? For instance, assume treatment for cancer X
is totally ineffective. Persons not
screened will be diagnosed later than persons in the screening arm of the
trial. Thus, the diagnosis-to-death
interval will be shorter for the first group than the second, and it will
appear the “progress is being made”, when in fact it hasn’t. In fact, the screened group is less well off
in that they had to live longer with anxiety.
So, I guess that screening is useful only for those cancers that are
easier to cure in an early stage. Ovarian
is one of these.